New hope for kids with MVID: drug aims to cut diarrhea and IV needs

NCT ID NCT06721871

Ongoing Disease control Sponsor: Napo Pharmaceuticals, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a drug called crofelemer in 6 children with microvillus inclusion disease (MVID), a rare condition causing severe diarrhea and dependence on IV fluids. The drug is given as a powder mixed with water, three times a day, and compared to a placebo. The goal is to see if it safely reduces diarrhea and the need for IV support.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: crofelemer
What this could lead to: If it works, crofelemer could reduce the severe diarrhea and need for IV fluids in children with MVID, improving their daily life.
What could go wrong: This is a very small early-stage trial (6 children), so results may not apply to all patients. The drug may not work better than placebo, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CONGENITAL DISORDERS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Congenital, Hereditary, and Neonatal Diseases and Abnormalities microvillus inclusion disease Rare Diseases

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CONGENITAL DISORDERS MICROVILLUS INCLUSION DISEASE RARE DISEASES

Contacts and locations

Locations

Al Jalila Children's Hospital

Dubai, United Arab Emirates
Boston Children's Hospital

Boston, Massachusetts, 02115, United States
UOS Gastroenterolgia e Riabilitazione nutrizionale Piazza Sant' Onofrio 4

Rome, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.